Bavarian Nordic AS (CHIX:BAVAC) Current Deferred Revenue: kr0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BAVAC Bavarian Nordic AS CHIX:BAVAC
79 GF Score
Price kr188.30
GF Value kr168.27
! 2 Warning Signs
View Full Analysis

What is Bavarian Nordic AS Current Deferred Revenue?

Bavarian Nordic AS CHIX:BAVAC 79 Current Deferred Revenue is kr0 Mil as of Mar. 2026. GuruFocus rates CHIX:BAVAC with a GF Score™ of 79/100 and a GF Value™ of kr168.27. The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Bavarian Nordic AS's current deferred revenue for the quarter that ended in Mar. 2026 was kr0 Mil.

Bavarian Nordic AS Current Deferred Revenue Related Terms

Bavarian Nordic AS Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Bavarian Nordic AS's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bavarian Nordic AS Current Deferred Revenue Chart

Bavarian Nordic AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bavarian Nordic AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:BAVAC
79GF Score
Bavarian Nordic AS CHIX:BAVAC
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of kr0 Mil mean?
Bavarian Nordic AS (CHIX:BAVAC) has a Current Deferred Revenue of kr0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bavarian Nordic AS and its competitors.
Is Bavarian Nordic AS's Current Deferred Revenue too high?
Bavarian Nordic AS's current Current Deferred Revenue is kr0 Mil. Overall, Bavarian Nordic AS has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Current Deferred Revenue compare to VRTX and REGN?
Bavarian Nordic AS's Current Deferred Revenue of kr0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bavarian Nordic AS and its competitors. Bavarian Nordic AS's current Current Deferred Revenue is kr0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Bavarian Nordic AS (CHIX:BAVAC) has a current Current Deferred Revenue of kr0 Mil. The stock's GF Value™ is kr168.27, compared to a current price of kr188.30 — trading 11.9% above its estimated fair value. The current Current Deferred Revenue is kr0 Mil. Bavarian Nordic AS's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Current Deferred Revenue is kr0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?

Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued. The current stock price of kr188.30 is trading 11.9% above its estimated GF Value™ of kr168.27.

Key valuation signals for CHIX:BAVAC:

  • Current Deferred Revenue: kr0 Mil
  • GF Value™: kr168.27 vs. price of kr188.30 (11.9% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bavarian Nordic AS Business Description

Address Philip Heymans Alle 3, Hellerup, DNK, 2900
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
79GF Score

Get the complete analysis for CHIX:BAVAC

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr188.30
Price
kr168.27
GF Value